報價延遲最少15分鐘:2025/05/14 06:19 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
21.58 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.75/-2.51
|
|
企業價值
1.49B
|
| 資產負債 |
|
每股賬面淨值
9.05
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/05/14 06:19 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. |